bioRxivNeurosciencePreprint
Identification of molecular and clinical ALS subgroups based on TDP-43 loss of function molecular markers from population-based patient-derived iPS motor neurons
T. L. Cheng, shaili tripathi, Yike Guo, Parimala Vedula, R. Li, Michael Potanin, Nidhi SoleyiD, April Yujie Yan, Ishan VatsarajiD, Carl HarrisiD, Joseph L. GreensteiniD, Casey Overby TayloriD, Alyssa N. CoyneiD, Jeffrey D. RothsteiniD
Abstract
BackgroundAmyotrophic lateral sclerosis (ALS) is a uniformly fatal neurodegenerative disease characterized by progressive cortical and spinal motor neuron loss, with most patients surviving only 2-5 years post-diagnosis. While approximately 10% of cases are familial (fALS), the remaining 90% are sporadic (sALS) with unknown genetic drivers. Importantly, clinical presentations are heterogeneous in both sporadic and familial ALS, underscoring the complexity of the disease. A pathological hallmark of ALS is the mislocalization of RNA-binding protein TDP-43 from the nucleus to the cytoplasm. This mislocalization produces both loss of function consequences, such as widespread RNA processing and splicing defects, as well as potential toxic gain of function effects associated with cytoplasmic aggregation. ResultsIn this study, we used RT-PCR data from induced pluripotent stem cell-derived motor neurons derived from 180 sALS and C9orf72 fALS patients from the Answer ALS collection to identify biological subgroups based on TDP-43 loss-of-function signatures. Spectral embedding revealed four distinct molecular clusters, including one subgroup genetically similar to controls and another with the most dysregulated mRNA expression, suggesting differing disease severity. Linear mixed models were then used to assess the longitudinal trajectory of over 90 clinical measures, and the between-cluster interaction effects were evaluated. Conclusions36 clinical outcomes showed significant differences across clusters, supporting the presence of biologically and clinically distinct ALS subtypes based on the TDP-43 associated pathogenic cascade. These findings demonstrate a critical role of RNA profiling in uncovering biologically meaningful subtypes of ALS, potentially allowing for more precise prognostic tools and the development of future personalized therapeutic approaches.
- organism: human
- assay: bulk RNA-seq
- research focus: clustering
- research focus: differential expression
- approach: statistical model
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Predictive Cellular Signatures from Live Human Motor Neurons Distinguish TDP-43 ALS and Enable ALS Subtype Stratification
Julia Kaye, Naufa Amirani, … Steven M. Finkbeiner·bioRxiv·Apr 24, 2026
- ALS molecular subtypes are a combination of cellular, genetic, and pathological features learned by deep multiomics classifiers
Kathryn O’Neill, Regina Shaw, … Molly Hammell·Cell ReportsPeer-reviewed·Mar 1, 2025
- Characterizing shared and distinctive molecular phenotypes across motor regions in ALS with and without TDP-43 pathology in a veteran cohort
Patricia Hayes Doyle, Shiva Kazempour Dehkordi, … Miranda E. Orr·bioRxiv·Aug 30, 2026
- Highly variable molecular signatures of TDP-43 loss of function are associated with nuclear pore complex injury in a population study of sporadic ALS patient iPSNs
Jeffrey D. Rothstein, Caroline Warlick, Alyssa N. Coyne·bioRxiv·Dec 12, 2023
- Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia
Oliver H. Tam, Nikolay V. Rozhkov, … John Ravits·Cell ReportsPeer-reviewed·Oct 1, 2019
- A panel of TDP-43-regulated splicing events verify loss of TDP-43 function in amyotrophic lateral sclerosis brain tissue
Maize C. Cao, Brigid Ryan, … Emma L. Scotter·Neurobiology of DiseasePeer-reviewed·Jul 30, 2023